Boardroom Media (CEO News)
At CEO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top San Francisco based CEO’ operating in the Health Diagnostics space. If you think a CEO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Trevor Martin
Co-Founder and CEO of Mammoth Biosciences
As co-founder and CEO of Mammoth Biosciences, Trevor Martin is focused on creating the world’s first CRISPR-based platform for disease detection, taking impactful CRISPR technology out of the lab and into the hands of doctors and consumers. Prior to co-founding Mammoth, Trevor completed his PhD in Biology at Stanford University, where he worked at the intersection of statistics and genetics. In addition to having taught a course in Statistics at Stanford, Trevor has penned educational guides for university courses across the globe. His work has been featured in outlets like FiveThirtyEight and The Atlantic.
Follow Trevor Martin:
About Mammoth Biosciences: Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Chris Mansi
CEO, Co-Founder of Viz
Dr Mansi is a former Neurosurgeon and the CEO of Viz.ai an Applied AI Healthcare company.They recently received FDA clearance for the first ever AI aided triage and notification platform, opening the door to AI in acute emergency healthcare. Chris is a clinician innovator, entrepreneur and optimist focused on increasing healthcare access, building and supporting great teams and improving provider experience. Viz.ai builds clinician facing products that enable and empower doctors, allowing them to provide the best care to patients, everytime, everywhere.
Follow Chris Mansi:
About Viz: Viz is a medical imaging company that helps optimize emergency treatment using deep learning technology.
Mike Nolan
Chief Executive Officer of Freenome
Mike brings nearly three decades of experience to his role as Freenome’s Chief Executive Officer, building on a proven record of delivering transformative diagnostic technologies that help clinicians drive better outcomes for their patients. Previously, Mike served as the company’s Chief Business Officer, where he led Freenome’s corporate and business development, product management, clinical development and operations, program management, and marketing teams. He also oversaw partnerships with biopharma companies, academic medical centers, and health systems where our multiomics platform is deployed to move research and medicine forward.
Follow Mike Nolan:
About Freenome, Freenome, Freenome: Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Philip Fung
Founder / CEO of Kit.com
Founder/CEO @Kit.com, Engineer #15 @Facebook
Follow Philip Fung:
About Kit.com: Kit.com is a home medical exams, delivered. Kit makes health testing simpler, easier and more reliable for your patients.
Drew Perkins
Co-Founder and CEO of Mojo Vision
Follow Drew Perkins:
About Mojo Vision: Mojo Vision is developing Mojo Lens, the world’s first AR smart contact lens with a built-in display that delivers Invisible Computing
Pranay Kapadia
Co-Founder & CEO of Notable
Pranay Kapadia is a VP of Product at Blend Labs.
Follow Pranay Kapadia:
About Notable: Notable is an AI-powered health start-up that automates and digitizes every physician-patient interaction.
Hesaam Esfandyarpour
Founder and CEO of Genapsys
Hesaam is the Founder and CEO of GenapSys Inc. He is an inventor of electronic DNA sequencing, a technology he developed during his PhD work at Stanford. Hesaam has dedicated the past decade of his life to the development of this novel DNA sequencing technology, which has at its core the convergence of multiple fields of science – engineering, chemistry, biology, and computing. Hesaam incubated the technology at the Stanford Genome Technology Center for a period of six years before securing licenses to the IP and incorporating GenapSys in January of 2010. He has grown GenapSys from just a handful of employees working out of Menlo Labs incubator space, to over 50 employees across seven functional teams. In 2012, Hesaam partnered GenapSys with StartX, an accelerator for the development of Stanford’s top entrepreneurs. He has raised approximately $50M for GenapSys in Seed, Series A, and Series B rounds of financing. Hesaam holds a PhD and MS in Electrical Engineering, and MSc Management degree, all from Stanford University. He earned his BS in Electrical Engineering with Honors from Sharif University of Technology in Tehran, Iran. When he is not at GenapSys HQ (which is rare!) you can find Hesaam spending time outdoors, hiking or spending time with family and friends. He is also a great lover of poetry, his favorite of which are poems by the Persian poet Saa’di.
Follow Hesaam Esfandyarpour:
About Genapsys: Transform the human condition by building a scalable, affordable genomic sequencing ecosystem that will support research and diagnostics
Sasan Amini
Co-Founder and CEO of Clear Labs
Sasan combined his academic expertise and passion for healthy living when he co-founded Clear Labs with a mission to set a new paradigm for food safety and quality. Prior to serving as the CEO of Clear Labs, he worked in the Advanced Research department at Illumina. Sasan earned his PhD in Genomics from Princeton and holds multiple patents and publications in the field.
Follow Sasan Amini:
About Clear Labs: Clear Labs is a provider of a fully-automated sequencing platform for turnkey diagnostics.
Fabien Beckers
Founder & CEO of Arterys
Fabien Beckers is the CEO and co-founder of Arterys, a cloud/deep learning startup that is disrupting the medical imaging space and building image-based precision medicine tools. Fabien has led the growth of the company from four co-founders to a team of 34 today. Under his leadership, the company has become a pioneer in cloud-based medical imaging software, offering the first FDA-cleared end-to-end cloud infrastructure for medical imaging. They key advantages of the platform being automatic aggregation of real-world data and ability to scale and distribute the processing of increasingly large, complex datasets. Fabien’s vision for the company is to accelerate data-driven medicine by building precision medicine tools based on the consistent quantification of medical image features in combination with molecular, genomics and patient history data. Fabien holds a PhD in Quantum Physics from the University of Cambridge and a masters of business from Stanford University.
Follow Fabien Beckers:
About Arterys: Arterys is a medical imaging platform to deliver clinical AI products over the internet.
Colleen Cutcliffe
Co-Founder and CEO of Pendulum Therapeutics
Colleen Cutcliffe is the Co-Founder and CEO of Pendulum Therapeutics.
Follow Colleen Cutcliffe:
About American Diabetes Association, California Life Sciences Association, Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Maneesh Jain
CEO and Co-Founder of Mirvie
Maneesh Jain currently works as Chief Executive Officer and the Founder of Mirvie. He previously worked at Cirina (Grail) as CEO and President.
Follow Maneesh Jain:
About Mirvie: Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.
Eric Schadt
CEO & Founder of Sema4
Eric Schadt is Chief Scientific Officer of Pacific Biosciences and Director of the Institute for Genomics and Multiscale Biology and Chair of the Department of Genetics and Genomics Sciences at The Mount Sinai Medical Center. He oversees the scientific strategy for Pacific Biosciences, including creating the vision for next-generation applications of the company’s technology, contributing to the evolution of Pacific Biosciences’ transformative sequencing technology, and playing a key role in the company’s strategic relationships. At Mount Sinai, Eric is creating a world-class data analytic center where researchers can query and learn from data using cutting-edge technologies like next generation sequencing to create disease models and ultimately help develop and improve the diagnosis and treatment of patients. He is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Eric Schadt joined Pacific Biosciences in May 2009 from Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, where he was Executive Scientific Director of Genetics. Eric Schadt’s work at Rosetta involved the generation and integration of very large-scale sequence variation, molecular profiling, and clinical data in disease populations to construct the molecular networks that define disease states and link molecular biology to physiology in ways that can impact clinical medicine. Eric Schadt has contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes and obesity, which have been widely published in leading scientific journals. His research has provided novel insights into what is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena. Prior to joining Rosetta, Eric Schadt was a senior research scientist at Roche Bioscience. He received his BA in applied mathematics and computer science from California Polytechnic State University, his MA in pure mathematics from UCLA, and his Ph.D. in bio-mathematics from UCLA.
Follow Eric Schadt:
About Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, Sage Bionetworks, Sema4: Sema4 uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.
Jonathan Winger
CEO of Omniox
Jonathan Winger is co-inventor of the H-NOX technology, company Co-Founder, and Senior Director of Biochemistry and Manufacturing. He directs the design and biochemical characterization of protein variants with the kinetic and stability properties appropriate for each of the diseases in which H-NOX will be used, as well as oversees in-house protein production and quality control. He also manages the transfer of upstream and downstream processes for scale-up and GMP manufacturing of material for toxicology studies and clinical trials. Jonathan has 18 years of experience in diverse biochemical and biophysical methods for production and study of H-NOX and other heme proteins. He has published a number of peer reviewed research papers, co-authored several book chapters, and is an inventor on multiple patents. Prior to Omniox, he was an American Heart Association Postdoctoral Fellow with John Kuriyan at the University of California, Berkeley, where he developed expertise in biophysical techniques including X-ray crystallography, small-angle X-ray scattering, and NMR. He obtained his PhD in Medicinal Chemistry with Michael Marletta at the University of Michigan, where he used spectroscopy and enzymology to investigate the role of soluble guanylate cyclase (sGC), an H-NOX domain-containing protein, in nitric oxide signaling pathways. Insights gained from this work contributed to the conception and founding of Omniox.
Follow Jonathan Winger:
About Omniox, Omniox: Omniox, a biotechnology company, commercializes technologies used in identifying and treating cancer, cardiovascular disease and trauma.
Harrison Gordon
Co-Founder and CEO of Blueberry Pediatrics
Harrison Gordon graduated from Northwestern University and worked for Microsoft as a program manager and Google as a product manager. With a family full of doctors and both parents practicing physicians based in Florida, Harrison wanted to use his background and expertise to create a company that uses online services to create a better life for everyone. In his spare time, Harrison enjoys cooking, hiking, and playing with his 1-year-old rescue dog Riley.
Follow Harrison Gordon:
About Blueberry Pediatrics: Blueberry Pediatrics provides parents with live access to top pediatricians for a flat monthly rate.
Xingjuan Chao
Co-founder and Chief Executive Officer of Ceribell
Follow Xingjuan Chao:
About Ceribell: Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective.
Neil Hunt
Founder and CEO of Curai Health
Neil Hunt has been at Netflix since 1999 and serves as Chief Product Officer, leading the product team, which designs, builds and optimizes the Netflix experience. Prior to Netflix, Neil worked from 1991 in various engineering and product roles at the software test tool companies Pure Software and its successors, Pure Atria and Rational Software. Before that, Neil was engaged in research in computer vision and image processing at the University of Aberdeen, Schlumberger Palo Alto Research Labs and Teleos Research. Neil has been a non-executive member of Logitech’s board of directors since September 2010. He holds a Doctorate in Computer Science from the University of Aberdeen, U.K. and a Bachelor’s degree from the University of Durham, U.K.
Follow Neil Hunt:
About Curai Health: Curai Health is a virtual care company that uses artificial intelligence to provide chat-based primary care at a lower cost.
Robert Ragusa
Chief Executive Officer of Grail
Follow Robert Ragusa:
About Grail, Illumina: Grail develops a pan-cancer screening test designed to detect cancers at an early stage.
Thomas Stanis
Co-Founder and CEO of Story Health
Thomas Stanis is the CEO and Co-Founder of Story Health. Prior to joining Verily, he spent nine years working on core Google products and five years at Electronic Arts. Throughout his career, Tom’s focus has been on improving the user experience, performance, and scalability of systems through cross-functional collaboration. He received his B.S. from UW Madison.
Follow Thomas Stanis:
About Story Health: Story Health helps specialists to understand medical situations and make clinical decisions that are through virtual protocols.
Octavian Florescu
CEO of Xip
Follow Octavian Florescu:
About Xip: Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
Helmy Eltoukhy
Co-founder & CEO of Guardant Health
Helmy is a serial entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Helmy was Sr Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.
Follow Helmy Eltoukhy:
About Guardant Health: Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs in oncology.
Bruce Patterson
CEO of IncellDx
Bruce Patterson is the CEO at IncellDx, Inc.
Follow Bruce Patterson:
About IncellDx, Stanford University School of Medicine: IncellDx is a molecular diagnostics company focused on the detection and monitoring of life threatening viral diseases.
Karen Drexler
CEO of Trak
Karen Drexler currently serves Sandstone Diagnostics as the chief executive officer and board member. She is also a member of the board of directors at ResMed and a founding member of Astia Angels. Prior to this, Karen spent over six years at Hygieia working as the chairman of the board. She is also co-founded Cellscape Corporation and was the CEO of Amira Medical for over five years. Karen received her MBA from Stanford University Graduate School of Business and her BSE in chemical engineering from Princeton University.
Follow Karen Drexler:
About Trak: Sandstone Diagnostics provides an integrated wellness technology that empowers consumers to measure, monitor, and improve their health.
Pavel Pravdin
Founder & CEO of Welltory
Pavel Pravdin is Welltory founder and CEO, ex-Director of Founder Institute, entrepreneur.As an engineer and a business leader, He has over 16 years’ experience in helping businesses achieve sustainable growth, reduce costs, and maximize profit through state-of-the-art technologies and business strategies.
Follow Pavel Pravdin:
About Adamantify, Welltory: The go-to health app that lets you read your body, track health, and sync gadgets.
Orestis Vardoulis
Co-Founder & CEO of Zeit Medical
Orestis Vardoulis currently works as the Co-Founder and CEO for ZeitMedical.
Follow Orestis Vardoulis:
About Zeit Medical: Zeit Medical provides peace of mind to neurology injury patients through powered AI and cutting edge Bioelectronics.
Jeffrey Dunn
President and CEO of SI-BONE
Jeffrey Dunn has over thirty years of executive experience, including serving as the CEO of six companies. His medical device experience includes sacroiliac surgery, ankle replacement, and small bone extremity fusion. Jeffrey Dunn has taken one company public, sold all the others to larger public companies, served on numerous boards of directors and is an advisor to other CEOs. Prior to SI-BONE, Inc. Jeffrey Dunn was CEO of INBONE Technologies, which he built into a leading ankle replacement and small bone fusion medical device company. Jeffrey Dunn led the sale of INBONE to Wright Medical in April, 2008. Jeffrey Dunn was the CEO of Active Decisions. Brought in to effect a turnaround, he closed down a major product line and redirected the technology to the “software as a service” model. Active Decisions was bought by Knova Software, a public company that was subsequently sold to Consona, a private equity firm. Previously, Jeffrey Dunn was the CEO of Velogic, an Internet performance testing software company. At Velogic, Jeffrey Dunn reinvented and expanded the product line, restructured the management team and created industry partnerships, one of which ultimately led to the acquisition of the company by Keynote Systems. Jeffrey Dunn was also the CEO of EnterpriseLink, a provider of enterprise Internet enablement software. Jeffrey Dunn was recruited to lead a turnaround by the investors. Jeffrey Dunn reinvigorated the company and successfully sold the company for a substantial gain in less than one year. Jeffrey Dunn was also the CEO of AccelGraphics, a 3D graphics systems supplier. Jeffrey Dunn created AccelGraphics by orchestrating a spin out from Kubota Graphics. He built the company into a rapidly growing enterprise (the 8th fastest growing Silicon Valley public company in 1997). The company was subsequently sold to Evans and Sutherland. Jeffrey Dunn has also held executive positions with Evans and Sutherland, Cygnet Systems, Avnet and Xerox. Jeffrey Dunn holds a BA degree from Colgate University and earned an MBA from Babson College.
Follow Jeffrey Dunn:
About SI-BONE: SI-BONE advances the diagnostic understanding of lower back pain and minimally invasive surgery for the sacroiliac joint.
Savan Devani
Founder & CEO of BioTrillion
Savan Devani is the Founder and CEO of BioTrillion, a health technology company developing a digital biomarker platform called BioEngine4D to digitally detect developing diseases. Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working with hundreds of public and private corporations as a healthcare investment banker with Citigroup and Deutsche Bank. From Analyst through Managing Director, Savan led 40 financing and M&A deals, totaling $35 billion in deal value, and learned many invaluable lessons working with clients across the drug, diagnostic, and device spectrum, such as Amgen, Eli Lilly, Fosun, Masimo, Medtronic, Pacific Biosciences, Xenoport, and many others. Savan began his career as a little bioengineer in a big lab at Life Technologies. Savan graduated with a B.S.E. in Bioengineering from the University of California at Berkeley and a M.S.E. in Bioengineering from the University of Pennsylvania. After many years of academic and professional experience in the healthcare field, a deeply personal experience later in life made Savan truly realize how much in healthcare needed to change – his mother was suddenly diagnosed with stage IVb cancer. This compelled Savan to ask “where were all the signs” and “isn’t there a better way,” which led to BioTrillion.
Follow Savan Devani:
About BioTrillion: Neural Nets for Neural Health””
John Fowler
Co-Founder and CEO of Kezar Life Sciences
Follow John Fowler:
About Kezar Life Sciences: Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders
Itamar Kandel
CEO of HeartVista.ai
Follow Itamar Kandel:
About HeartVista.ai: HeartVista is a medical technology company that provides one-click diagnostic imaging.
Guru Charan
Founder, CEO of Valley Oaks Medical Group
Follow Guru Charan:
About Valley Oaks Medical Group: Valley Oaks Medical Group offers healthcare services like family wellness, skin health screening, diagnostic imaging and X-rays.
Bonnie Anderson
Chief Executive Officer of Veracyte
Bonnie H. Anderson is Chairman of the Board, Chief Executive Officer and President of Veracyte, a pioneering genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in healthcare – enabling patients to get diagnosed sooner and avoid invasive surgeries and other costly procedures. Her career spans nearly 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008, took the company public in 2013 and has spearheaded Veracyte’s commercialization successes to date. Veracyte’s genomic tests are setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of thousands of patients avoid unnecessary surgery and other costly procedures. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. In 2015, Fast Company magazine named Ms. Anderson to its “100 Most Creative People in Business” list. She was named one of the “Most Influential Women in Bay Area Business” (2013) and one of the “Bay Area’s Most Admired CEOs” (2014) by the San Francisco Business Times, and has also received the Silicon Valley Business Journal’s “Women of Influence” award (2013).
Follow Bonnie Anderson:
About Veracyte: Veracyte develops molecular diagnostic tests to improve patient outcomes and lower healthcare costs.
Oded Harth
CEO & Founder of MDacne
Follow Oded Harth:
About MDacne: MDacne is a mobile platform that uses AI and computer vision to help people with acne.
Alejandro Tocigl
Co Founder & CEO of Miroculus
Alejandro Tocigl is CEO at miroculus.
Follow Alejandro Tocigl:
About Miroculus: Miroculus is a hands off sample-to-answer solution for molecular testing.
David Ge
CEO of Apostle
Dr. David (Dongliang) Ge is CEO & President of Apostle Inc (http://apostlebio.com), a Silicon-Valley-based biotechnology company developing a novel AI (Artificial Intelligence)-enabled NanoDiagnostics (AID) Technology for cancer detection at the early stage and other diagnosis and treatment of human diseases. Dr. Ge has had extensive experience in leadership roles in both American and Chinese biotechnology industry. Prior to Apostle, he was President of BioSciKin Co., Ltd., a China-based biotechnology company focusing on diagnostics, drug innovation, incubating, investing and licensing. Before BioSciKin, he was Director of Bioinformatics at Gilead Sciences, where he provided leadership to the corporate bioinformatics group and provided strategic input to the precision medicine infrastructure and process. Before Gilead, he was appointed as Assistant Professor of Medicine, Biostatistics and Bioinformatics at Duke University School of Medicine. in 2014 and 2015, Dr. Ge was appointed as member of U.S. NIH NHGRI Special Emphasis Panel. Dr. Ge received his PhD of Biostatistics and Genetic Epidemiology from Chinese Academy of Medical Sciences in 2004. He was named by the U.S. Genome Technology magazine as one of the “rising stars” in 2009 and by the U.K. Phacilitate as one of the “Top 50 Most Influential People in Big Data” in 2015. At Gilead, he and his colleagues contributed to the clinical development of Sofosbuvir, a world-leading anti-HCV drug. His work in discovering the IL28B genetic variants associated with the hepatitis C patients’ response to clinical treatment, published in Nature in 2009, has received over 3000 citations to date. In total, his work, including 5 original articles in Nature and 1 in Science, has received over 16,000 citations.
Follow David Ge:
About Apostle: Apostle Inc is a provider of innovative technologies and services for public health and life sciences.
Arjang Hassibi
Founder & CEO of Insilixa
Follow Arjang Hassibi:
About Insilixa: Insilixa is an organization focused on using high tech DNA testing for detection and treatment of pathogens that are antibiotic resistant.
Ajay Shah
Co-Founder, CEO of CytoVale
Follow Ajay Shah:
About CytoVale: Categorized is a medical technology company that revolutionizes diagnostics using cell mechanics and machine learning.
Akshay Nanduri
Co-Founder and CEO of Onc.AI
Follow Akshay Nanduri:
About Onc.AI: Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics.
Franco Goytia
Co-Founder & CEO of CASPR Biotech
Follow Franco Goytia:
About CASPR Biotech: CASPR Biotech develops a CRISPR-based platform for molecular detection.
Grace Colon
CEO, President and Director of InCarda Therapeutics
Dr. Grace Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. Her executive roles have spanned a broad range of functions in companies ranging from start-ups to publicly traded corporations. In addition to her role at InCarda, she serves on the board of directors of ProterixBio (Executive Chairman; formerly CEO), CareDx (NASDAQ:CDNA) and Cocoon Biotech, and formerly on the boards of Paradigm Diagnostics and PerceptiMed. She was also formerly a Partner and Senior Advisor at New Science Ventures, a NY-based venture capital firm with over $700M under management, and held executive and managerial roles at Intrexon Corporation, Gilead Sciences, Affymetrix, the International Genomics Consortium and McKinsey & Co. Dr. Colón received her Ph.D. from the Massachusetts Institute of Technology and a B.S. degree from the University of Pennsylvania, both in chemical engineering.
Follow Grace Colon:
About InCarda Therapeutics, ProterixBio: Incarda Therapeutics offers a novel approach to treat cardiovascular conditions and diseases by the inhalation route.
Jarret Glasscock
Founder & CEO of Cofactor Genomics
Jarret Glasscock is the Founder & CEO at Cofactor Genomics .
Follow Jarret Glasscock:
About Cofactor Genomics, Pioneer Fund: Cofactor Genomics builds multidimensional models of disease to deliver true precision medicine.
Syed Zafar Hamdani
Founder and CEO of DNAmito
Syed Zafar Hamdani is a seasoned veteran with twenty-five years of experience in systems software, storage and healthcare solutions. In his previous position as the CEO of Novasonics (Zonare), he led the company from the conception of their revolutionary ultrasound platform to the launch of their first product. Prior to that he was a senior executive at IBM responsible for the development, launch and P&L of IBM’s storage system platforms. Syed managed a global development and launch team of five hundred people between IBM divisions in San Jose, California; Rochester, Minnesota; and Fujisawa, Japan. His projects brought over three billion dollars of revenue to the company. Syed started his career as a system design engineer at Measurex and holds a M.S. in Electrical Engineering.
Follow Syed Zafar Hamdani:
About DNAmito: DNAmito is a predictive DNA sequencing startup.
Bernard Coulie
President & Chief Executive Officer of Pliant Therapeutics
Pliant CEO Bernard Coulie, M.D., Ph.D., brings to the company more than 15 years of senior leadership experience and drug development expertise. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was CEO, Chief Medical Officer and Co-Founder.In these positions, Coulie played an integral role in advancing the company’s unique technology platform for oral delivery of biologics from early discovery stage through Phase 2 studies. Prior to ActoGeniX, Coulie held various positions with increasing responsibilities in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. At Johnson & Johnson, he served as Therapeutic Area Leader Internal Medicine, managing a portfolio of products in GI, metabolic diseases and inflammation/immunology, ranging from early drug discovery through Phase 2 studies. Earlier in his career, Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic (Rochester, MN), Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Coulie holds an M.D. and Ph.D. from the University of Leuven, Belgium. He is a board-certified internist and he holds an MBA from the Vlerick Management School, Leuven, Belgium.
Follow Bernard Coulie:
About Pliant Therapeutics: Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Crystal Nyitray
CEO & Founder of Encellin
Follow Crystal Nyitray:
About Encellin: Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics.
Sander Gubbens
CEO of Ionpath
Follow Sander Gubbens:
About Gatan, Ionpath: Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies.
Henry Klyce
CEO of Active Implants
Henry Klyce is the CEO at Acitve Implants, LLC.
Follow Henry Klyce:
About Active Implants: Active Implants develops cushion-bearing orthopedic implant solutions.
Padideh Kamali-Zare
CEO, Founder, Chairperson of Darmiyan
Padideh is a world-renowned geometrical modeling expert with an outside-the-box thinking approach to complex problems. Her major skill is to put things into context and visualize the big picture (story-telling). She is an Adjunct Assistant Professor at New York University, School of Medicine, where she previously completed three years of postdoctoral training in biophysical neuroscience, 2010-2013. Padideh got her PhD in biological physics from Royal Institute of Technology (KTH) in Stockholm, Sweden in 2010. Her PhD thesis entitled “Biophysical mechanisms underlying cellular homeostasis” provided a non-classical explanation for the relationship between cell structure and function. In her free time Padideh enjoys teaching Persian classical music and writing blogs.
Follow Padideh Kamali-Zare:
About Darmiyan: Darmiyan is developing an AI-powered software platform for early detection, monitoring, and stratification of Alzheimer’s disease
Larry Hsu
President, CEO, Director of Impax Laboratories
President, CEO, Director at Impax Laboratories .
Follow Larry Hsu:
About Impax Laboratories: Impax is a technology-based, specialty pharmaceutical focused on controlled-release generic versions of brand-name pharmaceuticals.
Alice Rathjen
Co-Founder, CEO of DNA Compass
Health IT Entrepreneur Co-Founder, CEO DNA Compass http://www.dnacompass.com Advocate for consented patient-centric data , federated genome maps, security, privacy @dnatimes Example of reuse of mapping infrastructure for mapping and managing genomes at scale – https://www.dnabreast.com Slideshare – https://www.slideshare.net/dnatimes
Follow Alice Rathjen:
About DNA Compass: DNA Compass helps people meet up at locations on the genome to accelerate cures.
Kimberly Schreiber
Co-founder & CEO of NeuroNav
Kimberly Schreiber currently works as the Co-founder and CEO for NeuroNav. She previously worked at Off Grid Electric as the Product Manager.
Follow Kimberly Schreiber:
About NeuroNav: NeuroNav provides healthcare services to people with intellectual and developmental disabilities.
Hilary Jensen
Founder,CEO of Obe
Entrepreneur and Intrapreneur, Stanford BA, Harvard MBA, Google Alum, Successful Exit with Loopnet (acquired for $860million)
Follow Hilary Jensen:
About Obe: Digital Health Platform for Pet Parents and Veterinarians
Malekeh Amini
Founder & CEO of Trayt
Follow Malekeh Amini:
About AVA Health Technologies, Trayt: Trayt provides enterprise software for the health care sector to improve diagnosis and treatments in patients with brain-based disorders.
Stephanos Papademetriou
CEO & Founder of IntraVu
Stephanos Papademetriou is CEO Founder at IntraVu.
Follow Stephanos Papademetriou:
About Eve Biomedical, IntraVu, Oramic: IntraVu is a medical device company that transforms orthopaedic diagnostics.
Pablo Abad
Founder and CEO of Muvr
Follow Pablo Abad:
About Muvr: Muvr simplifies diagnostics and big data for orthopedic practices.
Ken Braslow
Founder/CEO of Luminello
Follow Ken Braslow:
About Luminello: Connecting and empowering mental health providers and patients
Bradford Goodwin
Co-Founder & Chief Executive Officer of CharlestonPharma,LLC
Bradford S. Goodwin, our Chief Executive Officer, is an experienced biotech executive. Mr. Goodwin also serves as a director of two public biotechnology companies: Rigel, Inc. and NeurogesX. Most recently he was Chairman of the Board of Facet Biotech Corp., a monoclonal antibody research and development company, which was sold to Abbott Laboratories for $722 million in April 2010. Previously he was Chairman of the Board of PDL BioPharma, a monoclonal antibody company earning $300 million per year in royalties, Chairman of the Board of CoTherix, Inc. a company commercializing Ventavis for pulmonary arterial hypertension that was sold to Actelion in 2007 for $420 million. From 2001 to 2006, he was Chief Executive Officer and Director of Novacea, Inc., an oncology drug development company that he built from a start up with one employee and one preclinical compound into a public company with three clinical stage products. At Novacea, he led four rounds of financings that raised over $140 million, including its IPO in 2006, and licensed two clinical stage compounds. He led the efforts to obtain a major corporate partnership for the company’s lead product, which was consummated shortly after he departed, with a total upfront payment of $72 million plus attractive royalties on product sales. Prior to Novacea, Mr. Goodwin was Vice President of Finance at Genentech, Inc. where he assisted in the commercialization of the first two FDA approved monoclonal antibodies for cancer: Rituxan® and Herceptin.
Follow Bradford Goodwin:
About CharlestonPharma,LLC, NeurogesX, Rigel: CharlestonPharma is focused on developing innovative therapeutic antibodies and related diagnostic tests for cancer patients.
Fangyu Liu
President and Chief Executive Officer of Handa Pharmaceuticals
With over 20 years of experience, Dr. Liu is an accomplished executive and scientist with a proven track record of building effective teams, technology-based product portfolios and successful pharmaceutical businesses. Dr. Liu founded Handa Pharmaceuticals in November 2005. Prior to founding Handa, he served as Chief Operating Officer and Vice President of Product Development and Operations at Anchen Pharmaceuticals from September 2002 to August 2005. As its first employee, Dr. Liu helped to set up Anchen’s business operations including formulation development, analytical services, quality assurance, information technology, regulatory affairs and a cGMP facility. Under his direction, the team successfully developed a pipeline of Paragraph IV controlled-release generic products, two of which were first-to-file. Prior to joining Anchen, Dr. Liu served in various management positions in product development and business development at Yamanouchi Pharma Technologies, where he developed and commercialized Benadryl® FastMelt Orally Disintegrating Tablets, among other proprietary products. From 1992 to 1997, Dr. Liu was employed by Impax Pharmaceuticals, Watson Pharmaceuticals, and Southern Research Institute, where he was credited with the development of several generic controlled-release products. Dr. Liu received a B.S. degree in Pharmacy from China Pharmaceutical University in 1983 and a Ph.D. degree in Industrial and Physical Pharmacy from Purdue University in 1992.
Follow Fangyu Liu:
About Handa Pharmaceuticals: Handa Pharmaceuticals, LLC (“Handa”) is a specialty pharmaceutical company established in the San Francisco Bay area in November 2005.
Bruno Thuillier
CEO of BOYDSense
Bruno’s career spans three decades in the mobile, automotive and medical industries, in various management positions in France, United Kingdom, Hong Kong, Germany and Silicon Valley. His expertise is in the fields of technology, R&D and business unit management. He held senior management positions at startups such as Sensitive Object acquired by TE Connectivity (NYSE: TEL) and Global Fortune 100 companies such as AT&T, Siemens and TE Connectivity. Bruno founded BOYDSense in 2015. He is CEO of this amazing startup, filled with passionate teams who care about enabling people with chronic conditions to live better and healthier lives. Previously, he was Chief Technology Officer of Sensitive Object, a startup acquired by TE Connectivity (NYSE: TEL). He developed a touch sensor technology that works on all type of surfaces and materials, enabling the deployment of new user interfaces for harsh environments in various industries, such as sensors and med tech. Earlier on, he was Vice President of Siemens Mobile Phone R&D at Global Fortune 100 company Siemens (Xetra: SIE). He assembled talented and successful teams in Germany, Denmark and US. He developed leading-edge mobile phones, focusing on the first mobile with a MP3 player, the first GSM-TDMA mobile for US market operated by AT&T, and the first Siemens mobile running on the Symbian OS operating system developed with Nokia. A Senior member of IEEE, Bruno is listed as an inventor on several patents. Bruno is a French-US dual citizen and live in San Francisco, California.
Follow Bruno Thuillier:
About BOYDSense: BOYDSense specializes in developing non-invasive and affordable tools for measuring critical biomarkers via the exhaled breath.
Eliott Jones
Founder and CEO of Biospectal
Follow Eliott Jones:
About Biospectal: Biospectal mission to reinvent medical sensing and monitoring through ubiquitous connected devices, IoT, and edge computing technologies.
Jim Justice
CEO of TouchHealth, Inc.
Jim Justice is the founder of TouchHealth, Inc., a collective effort of more than a dozen doctors and tech entrepreneurs with the goal of improving communications across the healthcare continuum. This is Jim’s umteenth startup company which has given him a broad real-world understanding of the startup and product development processes. He serves as an advisor and board member for various other tech companies.
Follow Jim Justice:
About iPIN, TouchHealth, Inc.: TouchHealth helps with communications between patients and healthcare professionals.
Mikhail Briman
Founder & CEO of Proxim Diagnostics
CEO at Proxim Diagnostics Corp.
Follow Mikhail Briman:
About Proxim Diagnostics: Proxim Diagnostics develops a next generation handheld immuno diagnostic device.
Karim Dabbagh
President and CEO of Second Genome
Follow Karim Dabbagh:
About Second Genome: Second Genome offers a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases.
